目的：分析miR-132在糖尿病视网膜病变(DR)患者血浆中的表达及与DR的关系。

方法：前瞻性研究，选取2015-07/10于我院确诊的55例糖尿病患者，按DR国际临床分期标准将患者分为5组。背景期：无明显视网膜病变组13例(A组)； 非增殖期(NPDR)33例，包括：轻度NPDR组10例(B组)，中度NPDR组11例(C组)，重度NPDR组12例(D组)； 增殖期(PDR)9例(E组)。另选取我院体检健康者12例作为健康对照组(F组)。应用实时荧光定量PCR(qRT-PCR)技术检测不同分期DR患者外周血浆中miR-132的相对表达量，并比较各组间差异。

结果：除无明显视网膜病变组外，其余各组DR患者与健康对照组相比，血浆中miR-132的表达水平均明显下降(P<0.05)； 非增殖期组间、非增殖期与增殖期组间比较，miR-132表达量无差异(P>0.05)。

结论：miR-132在NPDR和PDR患者血浆内低表达，可能成为DR治疗的生物标志物。

METHODS: From July 2015 to October 2015, a total of 55 patients with diabetes who were treated in our hospital were divided into 5 groups according to diabetic retinopathy clinical staging international standard, including 13 cases of no obvious retinopathy as group A, 10 cases of mild NPDR as group B, 11 cases of moderate NPDR as group C, 12 cases of severe NPDR as group D and 9 cases of PDR as group E, at the same time, the other 12 healthy people were enrolled as control group F. Real-time quantitative PCR(qRT-PCR)technique was used to detect the relative expression of miR-132 in the plasma of 55 patients with different stages of diabetic retinopathy and the expression difference between different groups were compared.

RESULTS: Compared with the healthy control group, the expression of miR-132 in the plasma was decreased in other groups(P<0.05)except in the background of diabetic retinopathy, however, there was no significant difference between the NPDR groups and the PDR groups.

CONCLUSION: The expression of miR-132 in the plasma of patients with DR was slightly lower in the non-proliferative and proliferative stage than in healthy subjects and background diabetic retinopathy. Furthermore, miR-132 may be a new biomarker for DR.